top of page

Mineralys CEO John Congleton describes the rational of targeting aldosterone for hypertension and discusses his company's pivotal data

  • Sep 8, 2025
  • 1 min read

He describes the science behind aldosterone and Mineralys' program lorundrostat. The company had pivotal data earlier this year and plans to have a pre-NDA meeting with FDA in the fourth quarter.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page